These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 16928403)

  • 1. Glucagon-like peptide 2 inhibits ghrelin secretion in humans.
    Banasch M; Bulut K; Hagemann D; Schrader H; Holst JJ; Schmidt WE; Meier JJ
    Regul Pept; 2006 Dec; 137(3):173-8. PubMed ID: 16928403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.
    Meier JJ; Nauck MA; Pott A; Heinze K; Goetze O; Bulut K; Schmidt WE; Gallwitz B; Holst JJ
    Gastroenterology; 2006 Jan; 130(1):44-54. PubMed ID: 16401467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
    Meier JJ; Gethmann A; Nauck MA; Götze O; Schmitz F; Deacon CF; Gallwitz B; Schmidt WE; Holst JJ
    Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1118-23. PubMed ID: 16403774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
    Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
    Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prandial regulation of ghrelin secretion in humans: does glucagon contribute to the preprandial increase in circulating ghrelin?
    Soule S; Pemberton C; Hunt P; Cole D; Raudsepp S; Inder W
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):412-7. PubMed ID: 16181233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
    Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
    Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
    Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects.
    Lerche S; Soendergaard L; Rungby J; Moeller N; Holst JJ; Schmitz OE; Brock B
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):500-6. PubMed ID: 19094067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion.
    Hagemann D; Holst JJ; Gethmann A; Banasch M; Schmidt WE; Meier JJ
    Regul Pept; 2007 Oct; 143(1-3):64-8. PubMed ID: 17434608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous CCK-8, but not GLP-1, suppresses ghrelin and stimulates PYY release in healthy men.
    Brennan IM; Otto B; Feltrin KL; Meyer JH; Horowitz M; Feinle-Bisset C
    Peptides; 2007 Mar; 28(3):607-11. PubMed ID: 17129639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.
    Meier JJ; Goetze O; Anstipp J; Hagemann D; Holst JJ; Schmidt WE; Gallwitz B; Nauck MA
    Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E621-5. PubMed ID: 14678954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No effect of beta-adrenergic blockade on hypoglycaemic effect of glucagon-like peptide-1 (GLP-1) in normal subjects.
    Toft-Nielsen M; Hvidberg A; Hilsted J; Dige-Petersen H; Holst JJ
    Diabet Med; 1996 Jun; 13(6):544-8. PubMed ID: 8799658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of growth hormone on high plasma levels of glucagon-like peptide-1 (GLP-1) in hypophysectomized rats.
    Tateishi K; Kitayama N; Ishikawa H; Mitsudome A; Hirose S
    Exp Clin Endocrinol Diabetes; 2002 Oct; 110(7):361-3. PubMed ID: 12397536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect.
    Prigeon RL; Quddusi S; Paty B; D'Alessio DA
    Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E701-7. PubMed ID: 12773303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations.
    Lucidi P; Murdolo G; Di Loreto C; Parlanti N; De Cicco A; Fatone C; Taglioni C; Fanelli C; Broglio F; Ghigo E; Bolli GB; Santeusanio F; De Feo P
    Nutr Metab Cardiovasc Dis; 2005 Dec; 15(6):410-7. PubMed ID: 16314227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 reduces the pulsatile component of testosterone secretion in healthy males.
    Jeibmann A; Zahedi S; Simoni M; Nieschlag E; Byrne MM
    Eur J Clin Invest; 2005 Sep; 35(9):565-72. PubMed ID: 16128863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of gastric emptying on the postprandial ghrelin response.
    Blom WA; Lluch A; Vinoy S; Stafleu A; van den Berg R; Holst JJ; Kok FJ; Hendriks HF
    Am J Physiol Endocrinol Metab; 2006 Feb; 290(2):E389-95. PubMed ID: 16188911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
    Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
    Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans.
    Meier JJ; Holst JJ; Schmidt WE; Nauck MA
    Am J Physiol Endocrinol Metab; 2007 Sep; 293(3):E849-56. PubMed ID: 17609256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.